Biotech Values

[hptaxis]

Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
https://investors.revance.com/news-releases/news-release-details/revances-rt002-demonstrates-unprecedented-efficacy-and-duration

– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines –
– The median time to return to baseline glabellar line severity was 28 weeks –
– RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year –
– Revance announces new trials in forehead lines and lateral canthal lines (crow’s feet) –
– Revance to host conference call at 8:30 am ET today –